

ECO Animal Health Group PLC

BLOCK LISTING RETURN

Date: 12 August 2024

Name of applicant:	ECO Animal Health Group plc		
Name of scheme:	Executive Share Option Scheme and Unapproved Share Option Scheme		
Number and class of securities originally listed and the date of admission:	1,500,000 ordinary shares of 5 pence each on 20 July 2017		
Period of return:	From:	09 February 2024	To: 09 August 2024
Balance of unallotted securities under scheme(s) from previous return:	375,505		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period:	0		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	375,505		

-Ends-

For further information please contact:

ECO Animal Health Group plc	
David Hallas (CEO)	020 8447 8899
Christopher Wilks (CFO)	
Singer Capital Markets (Nominated Adviser & Joint Broker)	020 7496 3000
Phil Davies	
Sam Butcher	
Investec (Joint Broker)	020 7597 5970
Gary Clarence	
Lydia Zychowska	
Equity Development	020 7065 2692
Hannah Crowe	
Matt Evans	
ICR Consilium (Financial PR)	020 3709 5700
Mary-Jane Elliott	ecoanimalhealth@consilium-comms.com
Jessica Hodgson	

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal

Carbadox product, *AVI-2000*, is a proprietary, powdered medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: <https://ecoanimalhealth.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRGPUUGGRUPCGPP